GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2021-10-15| Asia-Pacific

Dr. Reddy Stands as the First Indian Firm to Launch Cancer Drug in Chinese Market

by Tyler Chen
Share To

India’s Dr. Reddy’s Laboratories has made history as the first Indian firm to receive approval from China for an anticancer drug.

India’s Ambassador to China Vikram Misri tweeted on October 13, “a breakthrough for the Indian pharmaceutical industry in China as Abiraterone by Dr. Reddy’s Laboratories becomes the first anti-cancer drug from India to enter the Chinese market. Expect more success on this front.”

Generic Version of Janssen’s Zytiga

 

Dr. Reddy’s anti-cancer drug is a generic version of Janssen’s abiraterone acetate (Zytiga). Zytiga was approved by USFDA in February 2018 to be used in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). What’s more, the drug was approved in China in 2015 as a combination therapy to treat patients with mCRPC.

Statistics have shown that sales of abiraterone acetate substantially increased from 2016 to 2019. The annual sales revenue reached $88 million in 2019, a 30-fold jump in revenue compared to 2016. A report by ​​Research and Markets estimates sales of abiraterone in China “will continue to grow” in the next five years as the outlook of the Covid-19 pandemic improves. 

Dr. Reddy’s Moves on Cancer Drugs

 

In September 2021, Dr. Reddy launched Reddy-Lenalidomide, the generic version of Celgene’s oral cancer drug Revlimid, in Canada. It is one of the first generics of Revlimid in Canada, and it is used to treat patients with multiple myeloma.

The same month, the Indian firm sold the rights of its anti-cancer agent E7777 to Citius Pharmaceuticals, the deal of which is worth up to $150 million including  milestone payments. Dr. Reddy’s Laboratories acquired the drug in 2016 from the Japanese biotech Eisai.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
JPM 2025 Looks at the Cell and Gene Therapy Landscape – Autoimmune, Cancer, and Chronic Diseases are Front and Center
2025-01-21
Cecile Richards’s Battle with Glioblastoma
2025-01-21
Neuro, Pain, and Cancer Top the List at JPM 2025 Healthcare Conference
2025-01-17
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top